MITO News and Press, Stealth BioTherapeutics Corp. From 06/08/22

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium PR Newswire SBT-272 improved neuronal health, superior to other approved and investigational agents ...

European Medicines Agency (EMA) granted orphan drug designation to Stealth BioTherapeutics' (NASDAQ:MITO) elamipretide to treat myopathic mitochondrial DNA depletion syndrome (M-MDS). The company said the designation applies to patients with primary mitochondrial myopathy due to nuclear DNA m...

Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion Syndrome PR Newswire Orphan drug designation applies to patients with primary mitochondrial myopathy ...

Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022 PR Newswire New analysis demonstrates correlation between ellipsoid zone dysfunction and vision BOS...

Stealth BioTherapeutics (NASDAQ:MITO) shares have surged ~52% in the pre-market Thursday after the clinical-stage biotech announced that the FDA granted its Orphan Drug Designation for its lead asset elamipretide as a treatment for patients with Duchenne muscular dystrophy. In addit...

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy PR Newswire Pre-IND meeting request granted by FDA's Division of Neurology I BOSTON , May 12, 2022 /PRNewswire/ -- Stea...

Buying Penny Stocks on May 10th? Here’s What You Need to Know After another topsy turvy day of trading penny stocks and blue chips, there is a lot for investors to know. In the past few weeks, trading has been extremely difficult as a result of high inflation, rising interest rat...

Stealth BioTherapeutics (NASDAQ:MITO) is trading lower on Monday after the clinical-stage biotech said that its blindness therapy, elamipretide, did not meet the primary endpoint in a mid-stage trial for geographic atrophy (GA) secondary to dry age-related macular degeneration. The 176-patien...

STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY PR Newswire Study did not meet primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression Categorical i...

Stealth BioTherapeutics (NASDAQ:MITO) enters agreement with a single healthcare-focused institutional investor to purchase in a registered direct offering 5,583,028 ADS, representing ~67M ordinary shares. Purchase price is $0.6269 per ADS for gross proceeds of ~$3.5M. Each ADS represents...